So London Marathon 2018 - what an incredible day! A huge #TeamTSA thank you to absolutely everyone who has supported us at this event in every way - and most of all to Kris Stafferton, Huw Knight, Graham Sale, Richard Vennard and Jamie Wareing who have more than done
Managing the family finances can be a challenge at the best of times and especially so when you are caring for children or young people with additional needs or disabilities. Contact - For Families with Disabled Children is calling on mums, dads and other family
Are you interested in helping shape TSC research and direct how the TSA funds research? If so; we are looking for an additional lay (community) member of our research committee (RESCOM). Please see the attached guide and form for how to apply.  {module_literature filter="item"
Tuesday May 15 is TSC Global Awareness Day, the day we hope as many people as possible in the TS community worldwide will join together to help raise awareness of this rare disease by talking about it, online and offline. To help you to do
May 15 is #TSGlobalDay, the day on which the international Tuberous Sclerosis Community shares information and their stories about TSC to raise awareness of this condition, which affects an estimated 1 million people worldwide. Here are 15 facts about TSC which give the basics about
At the TSA we try to give everyone who engages with us an experience where they feel valued and supported. This includes people living with TSC, their families and carers as well as all of our amazing fundraisers and volunteers.  We have therefore decided to
The TSA is really pleased to hear of such positive results from a recent trial of topical rapamycin for the treatment of facial angiofibromas. The study, which took place in America and Australia and more details of which you can find on the link below,
A double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of Cannabidiol (GWP42003-P, CBD) as add-on therapy in patients with Tuberous Sclerosis Complex who experience inadequately-controlled seizures NCT02544763 How long is the study? Study length: 5 weeks of baseline and 16 weeks of treatment
 MEDIA RELEASE The Scottish Medicines Consortium (SMC) has announced today [Monday, 11 June] that everolimus will be available on prescription to treat refractory epilepsy in people aged two years and older with Tuberous Sclerosis Complex (TSC) in Scotland.  Maxine Smeaton, Chief Executive of
 The Clinical Priorities Advisory Group (CPAG) makes recommendations on NHS England’s approach to commissioning services, treatments and technologies, and considers which of these should be prioritised for investment. Its scope includes all specialised services provided by NHS England. The advisory group assesses drugs, medical
